β-AARC: Cohort Study for the Identification of Blood-based Biomarkers in a Population With Subjective Cognitive Decline

Active, not recruitingOBSERVATIONAL
Enrollment

200

Participants

Timeline

Start Date

May 25, 2021

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2025

Conditions
Alzheimer DiseasePreclinical AlzheimerMild Cognitive Impairment
Interventions
OTHER

Observational

"Cross sectional analyses The two main variables for the analysis will be: Values of biomarker concentrations in blood and their correlations with CSF biomarkers and the development of prodromal AD for the cognitively unimpaired SCD population. Other variables of interest for the study are, among others, risk factors, cognitive status, measurements of brain structure and function, mental health, chronic diseases, environmental exposures, age and sex.~Longitudinal analyses Longitudinal analyses will estimate the association between the intensity of the subjective complaint and the rate of progression between the diagnostic categories; The association of biomarkers, risk factors and other clinical variables with the rate of progression between the diagnostic categories; The association of cognitive and neuroimaging variables with the rate of progression between the diagnostic categories; The evolution of the complaint itself and its relation to the other variables described."

Trial Locations (1)

08005

BarcelonaBeta Brain Research Center, Barcelona

All Listed Sponsors
lead

Barcelonabeta Brain Research Center, Pasqual Maragall Foundation

OTHER

NCT04935372 - β-AARC: Cohort Study for the Identification of Blood-based Biomarkers in a Population With Subjective Cognitive Decline | Biotech Hunter | Biotech Hunter